Uterine papillary serous carcinoma (UPSC) is an atypical variant of endometrial carcinoma with a poor prognosis. It is commonly associated with an increased risk of extrauterine disease. The aim of this study was to investigate clinical and pathological characteristics, therapeutic methods, and prognostic factors in women with UPSC.
Methods
All patients who underwent surgery for UPSC at a single high-volume cancer center between January 1995 and December 2010 were retrospectively reviewed. Patients who did not undergo surgical staging and those with mixed tumor histology were excluded. Univariate and multivariate regression models were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).
Results
A total of 46 patients were included, the majority of whom having stage I disease (IA, 13 [28.2%] and IB, 12 [26.7%]). Stages II, III, and IV were identified in 5 (10.9%), 8 (17.4%), and 8 (17.4%) women, respectively. Optimal cytoreduction was obtained in 67.3% of patients. Recurrences developed in 8 (17.4%) patients. Multivariate analysis confirmed that lymphovascular space invasion (LVSI) (odds ratio [OR] 26.83, p = 0.003) was the only independent prognostic factor for OS, whereas LVSI and optimal cytoreduction were found to be independent prognostic factors for PFS (OR 6.91, p = 0.013 and OR 2.69, p = 0.037, respectively). The 5-year overall survival rate was 63%.
Conclusions
Our study demonstrated that LVSI is the only independent prognostic factor for OS, whereas LVSI and optimal cytoreduction are independent prognostic factors for PFS in patients with UPSC
KellyMG, O'MalleyD, HuiP, Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.Gynecol Oncol.2004;95(3):469–473.
2.
OlawaiyeAB, Rauh-HainJA, Withiam-LeitchM, RuedaB, GoodmanA, del CarmenMG.Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.Gynecol Oncol.2008;110(3):293–298.
3.
BenitoV, LubranoA, ArencibiaO, Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution.Int J Gynecol Cancer.2009;19(8):1364–1369.
4.
BristowRE, AsrariF, TrimbleEL, MontzFJ.Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I-III) disease.Gynecol Oncol.2001;81(2):279–286.
5.
BristowRE, DuskaLR, MontzFJ.The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.Gynecol Oncol.2001;81(1):92–99.
6.
HendricksonM, RossJ, EifelP, MartinezA, KempsonR.Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma.Am J Surg Pathol.1982;6(2):93–108.
SlomovitzBM, BurkeTW, EifelPJ, Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.Gynecol Oncol.2003;91(3):463–469.
9.
PiuraB, MeirovitzM, ShmulmanM, Yanai-tj.5000531InbarI, CohenY, DganiR.Uterine papillary serous carcinoma: study of 19 cases.Eur J Obstet Gynecol Reprod Biol.1998;79(1):69–73.
10.
ThomasMB, MarianiA, ClibyWA, KeeneyGA, PodratzKC, DowdySC.Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.Gynecol Oncol.2007;107(2):186–189.
HuangCY, TangYH, ChiangYC, Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.Gynecol Oncol.2014;133(2):221–228.
13.
CreasmanW.Revised FIGO staging for carcinoma of the endometrium.Int J Gynaecol Obstet.2009;105(2):109.
14.
ThomasMB, MarianiA, ClibyWA, KeeneyGL, PodratzKC, DowdySC.Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.Gynecol Oncol.2007;107(2):190–193.
15.
SoslowRA, BissonnetteJP, WiltonA, Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences.Am J Surg Pathol.2007;31(7):979–987.
16.
AmbrasRA, ShermanME, ZahnCM, BittermanP, KurmanRJ.Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.Hum Pathol.1995;26(11):1260–1267.
17.
ShermanME, BittermanP, RosensheinNB, DelgadoG, KurmanRJ.Uterine serous carcinoma.A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol.1992;16(6):600–610.
18.
CreasmanWT, KohlerMF, OdicinoF, MaisonneuveP, BoyleP.Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.Gynecol Oncol.2004;95(3):593–596.
19.
LambrouNC, Gómez-MarínO, MirhashemiR, Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival.Gynecol Oncol.2004;93(3):653–658.
20.
HavrileskyLJ, SecordAA, Bae-JumpV, Outcomes in surgical stage I uterine papillary serous carcinoma.Gynecol Oncol.2007;105(3):677–682.
ChanJK, LoizziV, YoussefM, Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.Gynecol Oncol.2003;90(1):181–185.
23.
GehrigPA, GrobenPA, FowlerWCJr, WaltonLA, Van LeL.Noninvasive papillary serous carcinoma of the endometrium.Obstet Gynecol.2001;97(1):153–157.
24.
GallionHH, van NagellJRJr, PowellDF, Stage I serous papillary carcinoma of the endometrium.Cancer.1989;63(11):2224–2228.
25.
GriceJ, EkM, GreerB, Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients.Gynecol Oncol.1998;69(1):69–73.
26.
DesaiNB, KiessAP, KollmeierMA, Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.Gynecol Oncol.2013;131(3):604–608.
27.
MollerKA, GehrigPA, Van LeL, SecordAA, SchorgeJ.The role of optimal debulking in advanced stage serous carcinoma of the uterus.Gynecol Oncol.2004;94(1):170–174.
28.
LackmanFD, CraigheadPS.Therapeutic dilemmas in the management of uterine papillary serous carcinoma.Curr Treat Options Oncol.2003;4(2):99–104.
29.
ChiDS, WelshingerM, VenkatramanES, BarakatRR.The role of surgical cytoreduction in Stage IV endometrial carcinoma.Gynecol Oncol.1997;67(1):56–60.
30.
BristowRE, ZerbeMJ, RosensheinNB, GrumbineFC, MontzFJ.Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.Gynecol Oncol.2000;78(2):85–91.
31.
Rauh-HainJA, GrowdonWB, SchorgeJO, Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.Gynecol Oncol.2010;119(2):299–304.
32.
HuhWK, PowellM, LeathCAIII, Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy.Gynecol Oncol.2003;91(3):470–475.
33.
FieldsAL, EinsteinMH, NovetskyAP, GebbJ, GoldbergGL.Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).Gynecol Oncol.2008;108(1):201–206.
34.
SecordAA, HavrileskyLJ, O'MalleyDM, A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.Gynecol Oncol.2009;114(3):442–447.
35.
GadducciA, CosioS, LandoniF, Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study.Int J Gynecol Cancer.2012;22(8):1355–1360.
